Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

KIRKSVILLE, Mo, — According to the U.S. Centers for Disease Control and Prevention (CDC), hospitals are seeing a high number of flu cases and a very high number of RSV cases. On top of that, while ...

Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

Human metapneumovirus (hMPV) is one of the viruses that causes the common cold. It usually makes people only mildly poorly, but it can make some people very sick. The NHS is under intense pressure ...

Respiratory syncytial virus (RSV) causes cold-like symptoms in most people but can cause more serious problems in some, especially babies and older adults. Almost all children get RSV at least once by ...

Featured pricing is subject to change. We know the feeling — the feeling of waltzing down a supermarket aisle to find the best protein bars, but getting too overwhelmed that we just put our ...

Nearly 80% of infants born during the late 2023 and early 2024 respiratory syncytial virus (RSV) season received protection against the virus, according to a recent study published in JAMA Network.